Answer： The requirement to sign a researcher's financial disclosure statement originates from the US FDA 21 CFR Part 54 "FINANCIAL DISCLOSURE BY CLINCIAL INVISITORS" (see https://www.fda.gov/scienceresearch/specialtopics/runningc ）This information serves as a consideration factor for the FDA to determine whether there is a conflict of interest among researchers and to determine whether the experimental data is true and reliable. The timeline and frequency of signing this statement can be found in 21 CFR Part 312, C (4) Financial disclosure information. Sufficient accurate financial information to allow the sponsor to submit complete and accurate certification or disclosure statements required under part 54 of this chapter. The sponsor shall retain a commitment from the clinical investor to promptly update this information if any relevant changes occur during the course of the investment and for 1 year Following the completion of the study To ensure the completeness and reliability of the collected information, it is necessary to consider providing a Chinese and English comparison for researchers to fully understand the content and purpose of this statement.